December 19, 2017 / 6:41 AM / a month ago

BRIEF-Nicox Updates on Drug Development And Outlines 2018 Activities

Dec 19 (Reuters) - NICOX SA:

* RESOURCES IN 2018 WILL BE FOCUSED ON ADVANCING NICOX‘S PIPELINE CANDIDATES NCX 470 AND NCX 4251 TOWARDS MID-STAGE CLINICAL DEVELOPMENT

* ESTIMATES THAT THE U.S. PATENTS COVERING VYZULTA COULD BE EXTENDED FROM 2025 TO 2030.

* EXPECTS TO BEGIN RECEIVING ROYALTY REVENUE IN 2018, ALONG WITH POTENTIAL SALES AND DEVELOPMENT MILESTONES PAYMENTS‍​

* NCX 470 TARGETING IND SUBMISSION FOR PHASE 2 IN 2018

* NCX 4251 TARGETING IND SUBMISSION FOR PHASE 2 IN 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below